For instance, the GLIOSTAR trial aims to investigate the potential effect of adding the pro-inflammatory cytokine tumor necrosis factor (TNF) combined with a tumor-targeted antibody (L19) to the standard recurrence therapy with lomustine (Look et al. 2023; NCT03779230). The gene discussed is TNF; the disease is neoplasm.